Table 2.
Company | Approach | Stage | Strategy |
---|---|---|---|
Arcturus Therapeutics | Vaccine | Phase 1/2 | Engineering RNA with nanoparticle |
BioNTech | Vaccine | Phase 3 | mRNA |
Zydus Cadila | ZyCoV-D vaccine | Phase 1/2 | RNA recombinant measles virus |
Mudoch Childre’s Research Institute | BCG vaccine | Phase 2/3 | Live attenuated virus |
Medicago, GSK, Dynavax | Plant-based vaccine | Phase 1 | Virus-like particle |
CureVac | Vaccine | Phase 1 | Man-made mRNA |
Eli Lilly | Treatment | Phase 3 | Antibody treatment |
GlaxoSmithkline+ Clover Biopharmaceuticals | Vaccine | Phase 1 | Engineering adjuvants with proteins |
Inovio Pharmaceuticals | Vaccine | Phase 1 | DNA vaccine |
Johnson & Johnson | Vaccine and treatment | Phase 1/2 | Deactivated virus |
Pfizer-BioNTech | Vaccine and treatment | Phase 2/3 |
Has not yet revealed strategy, five-point plan released RNA vaccine |
Regeneron Pharmaceuticals | Treatment | Phase 3 | Cocktail of antibodies |
Sanofi | Vaccine and treatment | Phase 3 | Chimera of RNA viruses, Kevzara drug |
Takeda | Treatment | Treatment phase | Plasma of treated patients |
Vir Biotechnology | Treatment | Phase 1 | Viral replication inhibitor |
Ascletis Pharma | Treatment | Phase 1b | Cocktail of danoprevir and titonavir |
Gamaleya Institute of Epidemiology and Microbiology | Vaccine | Phase 2 | Isolated strain |
Siberian Vector Institute | Vaccine | Phase 1 | Using a platform first developed for Ebola |
Moderna Therapeutics | Vaccine | Phase 3 | RNA vaccine (mRNA −1273) |
CanSino Biologics | Vaccine | To start phase 3 |
SARS-CoV-2 genetic code entwined in harmless virus Non-replicating virus |
Gilead Sciences | Treatment | Phase 3 | Remdesivir |
Oxford University | Vaccine | Phase 2/3 trial in UK, phase 3 trials in SA and Brazil |
AZD 1222 Non-replicating virus |
Bharat Biotech | Vaccine | Phase 1/2 | COVAXIN inactivated virus |